Related Experiment Video
Updated: Apr 16, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet treatment in essential hypertension: where do we stand?
Eugenia Gkaliagkousi1, Eleni Gavriilaki, Stella Douma
12nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Insights
Antiplatelet agents are crucial for cardiovascular risk. This review examines novel antiplatelet treatments, including aspirin and P2Y12 inhibitors, for essential hypertension patients, an understudied area.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a major public health issue linked to cardiovascular disease.
- Patients with hypertension often have additional cardiovascular risk factors and heightened platelet activation.
- Current antiplatelet treatment strategies for hypertensive individuals require further investigation.
Purpose of the Study:
- To review current experimental and clinical data on antiplatelet therapy in essential hypertension.
- To highlight recent advancements and novel agents in this therapeutic area.
- To critically assess the role of antiplatelet agents in managing cardiovascular risk in hypertensive patients.
Main Methods:
- Literature review of recent experimental and clinical studies.
- Critical analysis of data on aspirin, clopidogrel, and novel P2Y12 inhibitors.
- Evaluation of other agents with potential antiplatelet effects.
Main Results:
- The role of antiplatelet therapy in essential hypertension is not fully understood.
- Novel antiplatelet agents and aspirin show promise but require more research.
- Platelet activation is common in hypertensive patients with cardiovascular risk.
Conclusions:
- Further research is needed to establish optimal antiplatelet strategies for essential hypertension.
- Novel antiplatelet agents may offer new therapeutic avenues.
- Understanding platelet activation in hypertension is key to improving cardiovascular outcomes.
Abstract:
Antiplatelet agents represent a cornerstone in the management of patients at increased cardiovascular risk. Essential hypertension is considered a major public health problem leading to increased cardiovascular morbidity and mortality. The majority of patients with essential hypertension exhibit also additional cardiovascular risk factors and present with increased platelet activation. Despite recent innovations in the field of antiplatelet treatment and the introduction of novel agents, the role of antiplatelet treatment in patients with essential hypertension remains understudied. This review aims to shed light on novel experimental and clinical data in the evolving field of antiplatelet treatment in essential hypertension. In particular, recent data regarding aspirin, clopidogrel, novel P2Y12 inhibitors, and other agents with potential antiplatelet effects are critically reviewed.
More Related Videos
09:13Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:27Peripheral Artery Disease III: Interprofessional Care